Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug:187:37-45.
doi: 10.1016/j.ygyno.2024.04.016. Epub 2024 May 6.

Prognostic performance of the 2023 FIGO staging schema for endometrial cancer

Koji Matsuo  1 , Ling Chen  2 , Maximilian Klar  3 , Matthew W Lee  4 , Hiroko Machida  5 , Mikio Mikami  5 , Laila I Muderspach  4 , Joseph W Carlson  6 , Lynda D Roman  7 , Jason D Wright  8
Affiliations

Prognostic performance of the 2023 FIGO staging schema for endometrial cancer

Koji Matsuo et al. Gynecol Oncol. 2024 Aug.

Abstract

Objective: To assess the prognostic performance of the 2023 International Federation of Gynecology and Obstetrics (FIGO) endometrial cancer staging schema.

Methods: This retrospective cohort study queried the Commission-on-Cancer's National Cancer Database. Study population was 129,146 patients with stage I-IV endometrial cancer per the 2009 FIGO staging schema. Stage-shifting and overall survival (OS) were assessed according to the 2023 FIGO staging schema.

Results: Upstage (IA → II, 21.4 %; IB → II, 53.0 %) and downstage (IIIA→IA3, 22.2 %) occurred in both early and advanced diseases. Inter-stage prognostic performance improved in the 2023 schema with widened 5-year OS rate difference between the earliest and highest stages (68.2 % to 76.9 %). Stage IA1-IIB and IIC had distinct 5-year OS rate differences (85.8-96.1 % vs 75.4 %). The 5-year OS rate of the 2009 stage IIIA disease was 63.9 %; this was greater segregated in the 2023 schema: 88.0 %, 62.4 %, and 55.7 % for IIIA→IA3, IIIA1, and IIIA2, respectively (inter-substage rate-difference, 32.3 %). This 5-year OS rate of stage IA3 disease was comparable to the 2023 stage IB-IIB diseases (88.0 % vs 85.8-89.5 %). In the 2023 stage IIIC schema (micrometastasis rates: 29.6 % in IIIC1 and 15.6 % in IIIC2), micrometastasis and macrometastasis had the distinct 3-year OS rates in both pelvic (IIIC1-i vs IIIC1-ii, 84.9 % vs 71.1 %; rate-difference 13.8 %) and para-aortic (IIIC2-i vs IIIC2-ii, 82.9 % vs 65.2 %; rate-difference 17.7 %) nodal metastasis cases. The 5-year OS rate of the 2009 stage IVB disease was 23.4 %; this was segregated to 25.4 % for stage IVB and 19.2 % for stage IVC in the 2023 staging schema (rate-difference, 6.2 %).

Conclusion: The 2023 FIGO endometrial cancer staging schema is a major revision from the 2009 FIGO schema. Almost doubled enriched sub-stages based on detailed anatomical metastatic site and incorporation of histological information enable more robust prognostication.

Keywords: Cancer stage schema; Endometrial cancer; International Federation of Gynecology and Obstetrics; Prognostic performance; Revision; Survival.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest All were unrelated of the current study; consultant, Cardiff Oncology, Nutcracker, participation in the Steering Committee for the Global Coalition of Adaptive Research (L.D.R.); research grant, Merck, royalties, UpToDate (J.D.W.); research grant Bristol-Myers Squibb, honorarium, AstraZeneca (H.M.); consultant, AstraZeneca, CooperSurgical, and KLS Martin (M.K.); none for others.

Publication types

LinkOut - more resources